Faeth Therapeutics Highlights PIKTOR Strategy Ahead of Phase 2 Data
AUSTIN, Texas — September 8, 2026 Faeth Therapeutics announced plans to host a virtual key opinion leader (KOL) event...
Phase 2
Advertisement
Pulmovant Advances Mosliciguat Into Phase 3 After Positive PHocus Data
WALTHAM, Massachusetts — September 8, 2026 Pulmovant announced positive topline results from the Phase 2 PHocus study of mosliciguat...
BrainChild Bio Initiates Pivotal Phase 2 Trial of BCB-276 for DIPG
SEATTLE, Washington and CAMBRIDGE, Massachusetts — September 8, 2026 BrainChild Bio, Inc. announced the initiation of the pivotal Phase...
Monte Rosa Advances MRT-6160 Into Phase 2 for Sjögren’s Disease
BOSTON, Massachusetts — September 8, 2026 Monte Rosa Therapeutics, Inc. announced that Novartis has initiated a global Phase 2...
Nkarta to Present Initial NKX019 Autoimmune Data at ACR 2026
SOUTH SAN FRANCISCO, California — September 8, 2026 Nkarta, Inc. announced that three scientific presentations featuring NKX019 have been...
Advertisements
Upstream Bio Advances Verekitug Toward Phase 3 in Asthma
WALTHAM, Mass. — September 8, 2026 Upstream Bio, Inc. presented results from the Phase 2 VALIANT trial of verekitug...
Roivant and Pulmovant to Unveil Topline Mosliciguat Results in PH-ILD
Basel, Switzerland / London, UK / New York, NY — September 6, 2026 Roivant and Pulmovant announced that topline...
argenx Completes Forte Biosciences Acquisition for FB102
Amsterdam, the Netherlands – August 27, 2026 argenx announced the successful completion of its acquisition of Forte Biosciences, Inc.,...
Polaryx Advances SOTERIA Phase 2 Trial Readiness
PARAMUS, N.J. – August 25, 2026 Polaryx Therapeutics, Inc. announced continued operational progress toward initiating its SOTERIA Phase 2...
Spyre Reports SPY072 Rheumatoid Arthritis Phase 2 Results
WALTHAM, Mass. — August 25, 2026 Spyre Therapeutics, Inc. announced topline results from the rheumatoid arthritis (RA) sub-study of...
Advertisement
